Bookmark and Share

Ann M Farese
View Curriculum Vitae 

Ann M Farese M.A., M.S.

Academic Title: Assistant Professor
Primary Appointment: Radiation Oncology
Secondary Appointments: Pathology, Veterinary
afarese@som.umaryland.edu
Location: MSTF, 6-34D
Phone: (410) 706-5254
Fax: (410) 706-5270
Lab: (410) 706-5282

Personal History:

Ms. Farese began her research career in the Experimental Hematology Department at the Armed Forces Radiobiology Research Institute over 20 years ago. She has extensive experience with the effects of radiation injury in large animal models, particularly on the hematopoietic, immune and gastrointestinal systems. Ms. Farese is recognized nationally and internationally as an expert in cytokine-based treatment of myelosuppressed or myeloablated and stem cell-transplanted nonhuman primates and regularly reviews manuscripts for 7 journals. Ms. Farese has authored 36 peer-reviewed journal articles, 6 book chapters, 1 review, and 31 primary-authored abstracts and 87 co-authored, abstracts. Her work has been selected for presentation at special symposia focused on hematopoietic cytokines and she has given 30 oral presentations at national and international scientific and corporate-sponsored meetings.

Ms. Farese is a licensed medical technologist and she possesses 6 years of concentrated clinical hematology experience, of which three years were in the Clinical Hematology Department, Division of Clinical Pathology at the National Institutes of Healthâ?Ts Clinical Center. Her expertise in research, experimental design and laboratory skills and knowledge of hematology are based on over 10 years of experience in the clinical laboratory arena. Ms. Farese serves as co-investigator for the MacVittie laboratory and is the GLP laboratory manager for conduct of all experimental and clinical support of the rhesus macaques. Ms. Farese has served as the Study Director for several NIAID-sponsored, GLP-compliant studies. Ms. Farese is responsible for the overall execution of the experimental design and has daily, direct interaction with the research team and investigators. She is involved in all matters concerning experimental design and interaction with investigators and other projects. Ms. Farese has over 15 years of flow cytometry experience. She has collaborated extensively with technical personnel at BD/Pharmingen to establish the cross reactive antibody panel for rhesus macaques using human reagents, which allows a flow cytometry-based analysis for identification of dendritic cells, hematopoietic stem cells and their subsets.

Research Interests:

Radiation injury, hematopoietic growth factors, stem cells

Lab Techniques and Equipment:

Automated hematology instrumentation and flow cytometry


Publications:

MacVittie, T.J., Farese, A.M., Patchen, M.L., Myers, L.A. (1994) Therapeutic efficacy of recombinant interleukin-6 alone and combined with recombinant human interleukin-3 in a nonhuman primate model of high dose, sublethal radiation-induced marrow aplasia. Blood 84: 2515-2522.

Hunt, P., Li, L., Nichol, J.L., Hokom, M.M., Bogengerger, J. M., Swift, S. E., Skrine, J. D., Hornkohl, A. C., Lu, H., Clogston, C., Merewether, L. A., Johnson, M. J., Parker, V., Garcia, A., Farese, A., Hsu, R. Y., Garcia, A., Stead, R., Bosselman, R. A., Bartley, T. D. (1995) Purification and biological characterization of plasma-derived megakaryocyte growth and development factor (MGDF). Blood 86:540-547.

Farese, A.M., Hunt P., Boone, T., MacVittie, T.J. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal primates. Blood 86:54-59.

Farese, A.M., Herodin, F., McKearn, J.P., Baum, C., Burton, E., MacVittie, T.J. (1996) Acceleration of hematopoietic reconstitution using the synthetic cytokine, SC-55494 (a high affinity IL-3 receptor agonist) following radiation-induced, bone marrow aplasia. Blood 87:581-591.

MacVittie, T.J., Farese, A.M., Herodin, F., Baum, C., McKearn, J.P. (1996) Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine (SC-55494) and rhG-CSF. Blood 87:4129-4135.

Farese, A.M., Hunt, P., Grab, L. B., MacVittie, T. J. (1996) Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor. J Clin Inves 97:2145-2151.

MacVittie, T.J., Farese, A. M., Davis, T. A., Lind, L. B., McKearn, J. P. (1999) Myelopoietin, a chimeric agonist of human IL-3 and G-CSF receptors mobilizes more CD34+ cells and hematopoietic clonogenic cells in normal nonhuman primates relative to control growth factors: MPO mobilized CD34+ cells rapidly engraft lethally x-irradiated autologous hosts. Exp Hematol 72:1557-1568.

Rosenzweig, M., MacVittie, T.J., Harper, D., Hempel, D., Glickman, R. L., Johnson, R. P., Farese, A.M., Whiting-Theobald, N., Linton, G.F., Yamasaki, G., Jordan, C.T., Malech, H.L. (1999) Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates. Blood 94:2271-2286.

MacVittie, T.J., Farese, A. M., Lind, L. B., Baum, C. M., Burton, E., McKearn, J. P. (2000) Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 95:837-845.

MacVittie, T.J., Farese, A. M., Davis, T. A., Lind, L. B., McKearn, J. P. (2000) Myelopoietin, a chimeric agonist of human interleukin-3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates. Exp. Hematol . 27:1557-1568.

King, A., Horowitz, D., Dillon, S., Levin, R., Farese, A., MacVittie, T., Pelus, L. (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in Rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GROβ. Blood, 97:1534-1542.

Farese, A.M., Smith, W.G., Giri, J.G., Seigle, N., McKearn, J.P., MacVittie, T.J. (2001) Promegapoietin, an engineered chimeric IL-3 and mpl-L receptor agonist stimulates hematopoietic recovery in an abbreviated schedule following radiation-induced myelosuppression in nonhuman primates. Stem Cells, 19:329-338.

Farese, A.M., Casey, D.B., Smith, W.G., Vigneulle, R.M., McKearn, J.P., MacVittie, T.J. (2001) Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose and route of administration. Stem Cells,19:522-533.

MacVittie, T. J., Farese, A. M., (2002) Cytokine-based treatment of radiation-injury: Is there a potential benefit following low level radiation exposure. J. of Military Medicine, 167, Suppl. 1:068-070.

Farese, A.M., Smith, W.G., Giri, J.G., Seigle, N., McKearn, J.P., MacVittie, T.J. (2201) Promegapoietin, an engineered chimeric IL-3 and mpl-L receptor agonist stimulates hematopoietic recovery in an abbreviated schedule following radiation-induced myelosuppression in nonhuman primates. Stem Cells, 19:329-338.

Farese, A..M., Casey, D.B., Vigneulle,R.M., Siegel, N.R., Finn, R.F., Klover, J.A., Smith, W.G., McKearn, J.P., MacVittie, T.J. (2001) A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 19:514-521.

Farese, A.M., MacVittie, T.J., Roskos, L., Stead, R. B. (2003) Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: Effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 21:79-89.

Smith, D.E, Hanna, R., Friend, D., Moore, H., Chen, H, Farese, A..M, MacVittie, T.J., Virca, G.D., Sims, J.E., (2003) The soluble form of IL-1 receptor accessory protein is abundant in normal serum and enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87-96.

Cross, A.S., Sakarya, S., Rifat, S., Held, T.K., Drysdale, B.E., Grange, P.A., Cassels, F.J., Wang, L.X., Stamatos, N., Farese, A., Casey, D., Powell, J., Bhattacharjee, A.K., Kleinberg, M., Goldblum, S.E., (2003) Recruitment of murine neutrophils in vivo through endogenous sialidase activity. J. Biological Chemistry 278:4112-4120.

Farese, A.M., Yang, B-B., Roskos, L., Stead, R.B., MacVittie, T.J. (2003) Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplantation 32:399-404

Poliakova, L., Pirone, A.T., Farese, A.M., MacVittie, T.J., Farney, A. (2004) Presence of nonhematopoietic side population cells in the adult human and non-human primate pancreas. Transplantation Proceedings 36(4):1166-8.

Koopman G., Niphuis, H., Haaksma A.G., Farese, A. M., Casey, D.B., Kahn, L.E., Mann D., MacVittie, T.J., Woulfe, S. L., Heeney, J.L. (2004) Increase in plasmacytoid and myeloid dendritic cells by progenipoirtin-1, a chimeric Flt-3 and G-CSF receptor agonist, in SIV-infected rhesus macaques. Hum Immunol. 65(4):303-16.

MacVittie TJ, Farese AM, Jackson W 3rd. (2005) Defining the Full Therapeutic Potential of Recombinant Growth Factors in the Post Radiation-Accident Environment: The effect of supportive care plus administration of G-CSF. Health Phys. 89(5):546-55.

Koopman G, Mortier D, Niphuis H, Farese AM, Kahn LE, Mann D, Wagner R, Macvittie TJ, Woulfe SL, Heeney JL. (2005) Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy. Vaccine. 2005 May 13

Sebastian B., Ryser,M.F., Choi, U., Whiting-Theobald, N., Kuhlisch, E., Linton, G., Kang, E., Lehmann, R., Roesler, J., Rosen-Wolff, A., Rudikoff, A.G., Farese, A.M., MacVittie, T.J., Horwitz, M.E., Malech, H.L. (2005) Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after non-myeloablative transplantation with transduced autologous peripheral blood progenitor cells. Molecular Therapy, 14(2):202-11.